Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Procyclidine→

Procyclidine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
77-37-2
Molecular formula
C19H29NO
Molecular weight
287.4 g/mol
Drug class
Antimuscarinic antiparkinsonian agentcentral muscarinic acetylcholine receptor antagonist
Mechanism of action
Blocks central muscarinic acetylcholine receptors, restoring dopaminergic-cholinergic balance in basal ganglia circuits and reducing tremor and rigidity.
Indications / reported uses
  • Treatment of parkinsonian symptoms, including drug-induced extrapyramidal symptoms, in countries where procyclidine remains authorised; not all movement disorders respond and anticholinergic adverse effects limit use

Sources: NHS — Procyclidine · NLM MeSH — Procyclidine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Procyclidine Environmental Risk Assessment (ERA) (the Procyclidine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.